openPR Logo
Press release

Hemochromatosis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players are Novartis, ApoPharma Inc., La Jolla Pharmaceutical Company, DisperSol Technologies, LLC, Silence Therapeutics plc

06-06-2019 01:17 PM CET | Health & Medicine

Press release from: Pharma Proff

Hemochromatosis Therapeutics Pipeline to Witness Significant

Hemochromatosis, also known as iron overload, is identified as increased level of iron in the body. It has symptoms such as joint pain, weight loss, erectile dysfunction in men, and irregular menstrual cycle in women. Hemochromatosis can be categorized into two types: primary hemochromatosis and secondary hemochromatosis. Primary hemochromatosis is genetic disorder; however, secondary hemochromatosis occurs due to medical conditions such as anemia, thalassemia, and others.

Download the sample report at: https://www.pharmaproff.com/request-sample/1231

If hemochromatosis is not diagnosed or treated at an early stage, it may lead to some serious complications such as liver damage, diabetes, arthritis, reproductive complications, and cardiovascular diseases. The commonly used diagnostic techniques are blood test, and physical examination. Additional liver function test (LFT), magnetic resonance imaging (MRI), and liver biopsy procedures are performed to confirm the disease.
Exjade by Novartis International AG, and Ferriprox by ApoPharma Inc. are the two key U.S. Food and Drug Administration (USFDA) approved drugs for the treatment of hemochromatosis.

Browse Detailed Report at:https://www.pharmaproff.com/report/iron-overload-therapeutics-pipeline

According to the research findings, majority of pipeline drug candidates are being developed for oral administration. It has been observed that oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Administration of therapeutics for hemochromatosis through the oral route has shown promising results in clinical studies.

Companies that are involved in developing therapeutics for hemochromatosis have shown positive clinical results in various phases of drug development. For instance, in September 2016, La Jolla Pharmaceutical Company demonstrated positive results from a phase I study of LJPC-401 in patients with hereditary hemochromatosis, thalassemia, and sickle cell diseases. Results of the study were positive as LJPC-401 was well-tolerated with no dose limiting toxicities. Furthermore, in March 2019, La Jolla Pharmaceutical Company announced in its financial report that topline results of LJPC-401 in patients with hereditary hemochromatosis are expected in second half of 2019.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1231

As of 2018, Exjade and Ferriprox are two marketed products available in the market for the treatment of hemochromatosis. Due to emergence of late- and mid-stage pipeline products, the overall hemochromatosis therapeutics market is expected to grow significantly in the upcoming years.
Novartis International AG, ApoPharma Inc., La Jolla Pharmaceutical Company, DisperSol Technologies, Silence Therapeutics plc, and Vifor Pharma Management Ltd. are some of the key companies involved in the development of drug candidates for the treatment of hemochromatosis.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemochromatosis Therapeutics Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Top Key Players are Novartis, ApoPharma Inc., La Jolla Pharmaceutical Company, DisperSol Technologies, LLC, Silence Therapeutics plc here

News-ID: 1766697 • Views: 866

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Hemochromatosis

Hemochromatosis Treatment Market Intelligence Study for Comprehensive Insights
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate
Hemochromatosis-Global Drug Forecast and Market Analysis to 2026
Summary:                                      ReportsWeb.com published “Hemochromatosis-Global Drug Forecast and Market Analysis to 2026” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, Publisher expects this market to undergo substantial growth between 2016 and 2026, doubling over the
Hemochromatosis Treatment Market Trends and Growth Drivers Analysis 2025
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate
Hemochromatosis Treatment Market is Expected to Boost Up by 2025
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate
Hemochromatosis (Genetic Disorders) pipeline Forecast, H1, 2017- Pharmaceutical …
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free
Hemochromatosis Treatment Market : In-Depth Analysis Research Report 2017-2025
Hemochromatosis is nothing but an unusual accumulation of iron in the parenchymal organs. The over-accumulation of iron leads to a toxic condition in the organs. Hemochromatosis is a very common autosomal rHemochromatosis is also diagnosed by imaging tests which include chest radiography and echocardiography, CT scanning and sometimes MRI may also be helpful in evaluating hepatic iron quantification. Diagnostic endoscopy, skin endoscopy, and liver biopsy can be used to evaluate